Skip to content
ClinCalc Pro
Menu
Low molecular weight heparin

Tinzaparin sodium

Brand names: Innohep

Tinzaparin is a low-molecular-weight heparin given by subcutaneous injection for the prophylaxis and treatment of venous thromboembolism.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It potentiates antithrombin, principally inhibiting activated factor Xa (with some antithrombin activity), thereby reducing thrombin generation and clot formation.

Prescribing in practice

  • Bleeding is the main risk; assess bleeding risk before and during treatment.
  • It accumulates in renal impairment (use with caution and consider anti-Xa monitoring), and platelets should be monitored for heparin-induced thrombocytopenia.
  • Around neuraxial (spinal or epidural) anaesthesia there is a risk of spinal/epidural haematoma, so observe the recommended timing intervals.

Monitoring

Monitor for bleeding, check platelet counts for heparin-induced thrombocytopenia, and consider anti-Xa activity in renal impairment, extremes of body weight or pregnancy; note it is only partially reversed by protamine.

Counselling the patient

  • Tell your healthcare team straight away about any unusual bruising or bleeding, such as nosebleeds, blood in your urine or stools, or black stools.
  • If you give the injections yourself, you will be shown how to do this and how to rotate the injection sites.
  • Mention this medicine before any planned spinal or epidural procedure or surgery.

Evidence & guidelines

An established low-molecular-weight heparin in NICE guidance on venous thromboembolism prophylaxis and management.

Reference: NICE NG158; BSH; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.